Again, a Copenhagen-based biomanufacturing technology company, has acquired Genomatica (Geno), combining Geno’s computational biotechnology and molecule design capabilities with Again’s bioprocess design and scale-up technologies. Terms of the transaction were not disclosed.

The acquisition adds Geno’s artificial intelligence (AI) and computational platform, including capabilities for pathway and strain design, machine learning analytics, and de novo molecule discovery. Again said the combined platform will integrate these capabilities with its AI-driven bioprocess design and scale-up modeling tools.

According to the announcement, the combined technologies are intended to shorten the development path from pathway design to industrial-scale production. The platform will support development across multiple feedstock sources and is designed to integrate computational design with process engineering and manufacturing scale-up.

The transaction also adds Geno’s data and patent portfolio, including experimental results, structural and scale-up data, as well as development outcomes. Again said incorporating the data into its computational systems is intended to improve modeling and reduce development timelines.

The combined company will operate across the production lifecycle, from pathway discovery and design through industrial-scale manufacturing. The commercial model will include technology licensing, co-development of production pathways, and direct product sales from existing and planned manufacturing assets.

The acquisition comes as governments seek to expand domestic bio-based manufacturing and supply chains. Again cited initiatives including the U.S. BIOSECURE Act and the European Union’s Biotech Act II as potential drivers of investment in biomanufacturing infrastructure.